Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2013 1
2014 1
2015 3
2016 2
2017 1
2018 1
2021 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean duffin j (379 results)?
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
Foltynie T, Gandhi S, Gonzalez-Robles C, Zeissler ML, Mills G, Barker R, Carpenter J, Schrag A, Schapira A, Bandmann O, Mullin S, Duffen J, McFarthing K, Chataway J, Parmar M, Carroll C; EJS ACT-PD Consortium. Foltynie T, et al. Among authors: duffen j. Brain. 2023 Jul 3;146(7):2717-2722. doi: 10.1093/brain/awad063. Brain. 2023. PMID: 36856727 Free PMC article.
Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.
Gonzalez-Robles C, Weil RS, van Wamelen D, Bartlett M, Burnell M, Clarke CS, Hu MT, Huxford B, Jha A, Lambert C, Lawton M, Mills G, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Schrag A; EJS ACT-PD Consortium. Gonzalez-Robles C, et al. J Parkinsons Dis. 2023;13(6):1011-1033. doi: 10.3233/JPD-230051. J Parkinsons Dis. 2023. PMID: 37545260 Free PMC article. Clinical Trial.
A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease.
Godinho C, Domingos J, Cunha G, Santos AT, Fernandes RM, Abreu D, Gonçalves N, Matthews H, Isaacs T, Duffen J, Al-Jawad A, Larsen F, Serrano A, Weber P, Thoms A, Sollinger S, Graessner H, Maetzler W, Ferreira JJ. Godinho C, et al. Among authors: duffen j. J Neuroeng Rehabil. 2016 Mar 12;13:24. doi: 10.1186/s12984-016-0136-7. J Neuroeng Rehabil. 2016. PMID: 26969628 Free PMC article. Review.
IL-13 Controls IL-33 Activity through Modulation of ST2.
Zhang M, Duffen JL, Nocka KH, Kasaian MT. Zhang M, et al. Among authors: duffen jl. J Immunol. 2021 Dec 15;207(12):3070-3080. doi: 10.4049/jimmunol.2100655. Epub 2021 Nov 17. J Immunol. 2021. PMID: 34789557
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Brundin P, et al. Among authors: duffen j. J Parkinsons Dis. 2013 Jan 1;3(3):231-9. doi: 10.3233/JPD-139000. J Parkinsons Dis. 2013. PMID: 24018336 Free PMC article. Review.
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative.
Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, Mursaleen L, Schwarzschild MA, Stott SRW, Sulzer D, Svenningsson P, Tanner CM, Carroll C, Simon DK, Brundin P. Wyse RK, et al. Among authors: duffen j. J Parkinsons Dis. 2024 Apr 5. doi: 10.3233/JPD-230363. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38578902 Review.
Modulation of the IL-33/IL-13 Axis in Obesity by IL-13Rα2.
Duffen J, Zhang M, Masek-Hammerman K, Nunez A, Brennan A, Jones JEC, Morin J, Nocka K, Kasaian M. Duffen J, et al. J Immunol. 2018 Feb 15;200(4):1347-1359. doi: 10.4049/jimmunol.1701256. Epub 2018 Jan 5. J Immunol. 2018. PMID: 29305434
A protein kinase C α and β inhibitor blunts hyperphagia to halt renal function decline and reduces adiposity in a rat model of obesity-driven type 2 diabetes.
Wang J, Casimiro-Garcia A, Johnson BG, Duffen J, Cain M, Savary L, Wang S, Nambiar P, Lech M, Zhao S, Xi L, Zhan Y, Olson J, Stejskal JA, Lin H, Zhang B, Martinez RV, Masek-Hammerman K, Schlerman FJ, Dower K. Wang J, et al. Among authors: duffen j. Sci Rep. 2023 Oct 7;13(1):16919. doi: 10.1038/s41598-023-43759-7. Sci Rep. 2023. PMID: 37805649 Free PMC article.
16 results